Could a Stress-Blocking drug help veterans with PTSD?

NCT ID NCT07187011

Not yet recruiting Symptom relief Sponsor: San Diego Veterans Healthcare System Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2a trial will test whether PT150, a drug that blocks a stress-related receptor, can safely reduce PTSD symptoms in 120 US veterans. Participants will receive either PT150 or a placebo for several weeks, and researchers will track changes in PTSD severity and side effects. The goal is to see if PT150 is promising enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PT150 (a drug that blocks glucocorticoid receptors)
What this could lead to: If successful, this could point toward a new treatment option for PTSD in veterans, potentially easing symptoms like intrusive thoughts and hyperarousal.
What could go wrong: This is an early Phase 2a trial with only 120 participants, so results may not apply broadly. The drug may cause side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTSD - POST TRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

combat disorder injury post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PTSD - POST TRAUMATIC STRESS DISORDER

Contacts and locations

Locations

Jennifer Moreno Department of VA Medical Center

San Diego, California, 92161, United States
Michael E DeBakey VA Medical Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.